COVID-19 has put the biopharma industry into a tailspin – big pharma, biotech and small startups are all emerging in the development of a treatment and vaccine for this pandemic. Will COVID-19 change the current R&D landscape and create a new norm for the biopharma industry? Register Now
During this S3 virtual chat, we will discuss:
– What lessons have we learned to better respond to emerging diseases in the future.
– How do we advance promising therapies through preclinical testing but also ensure quick efficient clinical testing?
– How real-time analysis and AI-driven decision-making can assist in streamlining research
– What will the new norm look like?
President and CEO, Arizona BioIndustry Association (AZBio)
Co-Founder and CEO, Sanguine
Director of Preclinical Research, Infectious Diseases at Noble Life Sciences Inc
Chris Moore, PhD
Senior Director, Immunology, Arbutus Biopharma, Inc.